Biotech Strategy & M&A Support

I help biotech scale-ups become investor-ready by strengthening their strategy, operations, and program execution to secure funding or navigate M&A with confidence.

Biotech scale-ups operate in high-velocity environments where scientific progress, funding cycles, and operational complexity collide. To secure investment or navigate an M&A process, companies must demonstrate clarity, readiness, and operational excellence—not just scientific potential.

My role: help you prepare your organization, operations, and teams to face investors with confidence and credibility.

🧭 What I Deliver

1. Investment & M&A Readiness Assessment

Analysis of your operational maturity (PMO, CMC, R&D, G&A)
Identification of strategic gaps that matter to investors
Review of governance, processes, and program visibility
Prioritization roadmap to move quickly toward investor expectations

2. Operational & Strategic Structuring

Strengthening of project governance and cross-functional alignment
Streamlining of decision-making and program monitoring
Risk mapping, mitigation plans, and documentation cleanup
Preparation of data rooms (program, operational, and planning materials)

3. Support for Due Diligence & Transactions

Preparation of key materials (timelines, assumptions, strategic plans)
Clarification of execution risks and mitigation strategies
Coaching for leadership teams on investor-facing discussions
External representation for program strategy or operational defense

4. Post-Investment Execution Support

90-day execution roadmap to activate investor expectations
Strengthening of PMO and operational processes
Alignment of teams around new priorities
Acceleration of growth initiatives (scale-up hiring, AI adoption, international programs)

🎯 Who This Is For

Biotech companies who want to:

Raise a new round (Seed → Series C)
Prepare for acquisition or strategic partnership
Strengthen their operational credibility before meeting investors
Fix execution gaps that slow growth
Align leadership and teams around a clear scaling strategy

🚀 Your Benefit

A stronger, clearer, more investable organization — with solid operational foundations, a credible growth plan, and a leadership team fully prepared to engage with investors.

You don’t just “prepare a pitch”.
You become investor-ready.

When a biotech grows fast and the stakes rise even faster, you need more than a good story — you need a strategy that makes investors lean in and acquirers move closer.

A mid-size European biotech preparing for Series C was approached by a global pharmaceutical group interested in a potential strategic acquisition.

The science was strong, but the organisation lacked M&A readiness: documentation scattered across teams, inconsistent operational narratives, unclear quality maturity, and weak cross-functional alignment. The leadership team needed a single objective partner able to simplify complexity, strengthen the strategic story, prepare the teams for scrutiny, and accelerate the deal process — without slowing ongoing clinical operations.

When I joined the executive committee, we began an intensive strategy and M&A-readiness journey.

I reframed the company’s positioning around a sharper, investor-oriented narrative; aligned scientific, regulatory, quality, and commercial messages; and rebuilt a clean, coherent operational backbone that could withstand deep-dive due diligence.

Over several weeks, we clarified KPIs, streamlined documentation, stress-tested the clinical and CMC plans, and coached functional leaders to communicate with precision and confidence.

The goal was simple: make the company easier to understand, easier to trust, and easier to acquire.

The transformation was immediate and visible.

Internal friction dropped, decision cycles accelerated, and investor discussions became more fluid. The acquiring pharma group repeatedly highlighted the “exceptional clarity and operational maturity” of the company’s preparation. The deal progressed faster than expected, with significantly reduced negotiation friction and a stronger valuation thanks to the improved strategic coherence.

"Stéphane made us truly M&A-ready — he sharpened our strategy, aligned our teams, and turned a complex acquisition process into a confident, high-value success.

Great biotechs don’t get acquired by chance — they get acquired because they show up with discipline, coherence, and a strategy that commands trust.

Join us today to unlock the potential of your projects and propel your business to new heights of success.

Start your journey towards success today!

How to simplify your strategic approach?

Get our free methodology